| Bioactivity | CRX-526 is a TLR4 antagonist that can block the interaction of lipopolysaccharide (LPS, HY-D1056) with the immune system, including preventing the expression of pro-inflammatory genes stimulated by LPS, as well as blocking the release of TNF-α induced by LPS. CRX-526 exhibits anti-inflammatory effects in two mouse models of colitis (namely, the dextran sodium sulfate-induced colitis model and the multidrug resistance gene 1a-deficient mouse model)[1]. |
| CAS | 245515-64-4 |
| Formula | C69H127N2O19P |
| Molar Mass | 1319.72 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Fort MM, et al. A synthetic TLR4 antagonist has anti-inflammatory effects in two murine models of inflammatory bowel disease. J Immunol. 2005 May 15;174(10):6416-23. |
CRX-526
CAS: 245515-64-4 F: C69H127N2O19P W: 1319.72
CRX-526 is a TLR4 antagonist that can block the interaction of lipopolysaccharide (LPS, HY-D1056) with the immune system
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.